R
Robert Huddart
Researcher at Institute of Cancer Research
Publications - 440
Citations - 25190
Robert Huddart is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Bladder cancer & Radiation therapy. The author has an hindex of 76, co-authored 411 publications receiving 21783 citations. Previous affiliations of Robert Huddart include Gloucestershire Hospitals NHS Foundation Trust & Lancashire Teaching Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P. Dearnaley,Matthew R. Sydes,John Graham,Edwin Aird,David Bottomley,Richard A Cowan,Robert Huddart,Chakiath C Jose,John H L Matthews,Jeremy Millar,A. Rollo Moore,Rachel C Morgan,J. Martin Russell,Christopher D Scrase,Richard Stephens,Isabel Syndikus,Mahesh K. B. Parmar +16 more
TL;DR: The first analyses of effectiveness from the MRC RT01 randomised controlled trial are presented, finding Escalated-dose CFRT with neoadjuvant androgen suppression seems clinically worthwhile in terms of bPFS, progression-free survival, and decreased use of salvage androgens suppression.
Journal ArticleDOI
Multiple newly identified loci associated with prostate cancer susceptibility.
Rosalind A. Eeles,Rosalind A. Eeles,Zsofia Kote-Jarai,Graham G. Giles,Graham G. Giles,Ali Amin Al Olama,Michelle Guy,Sarah Jugurnauth,Shani Mulholland,Daniel Leongamornlert,Stephen M. Edwards,Jonathan J. Morrison,Helen I. Field,Melissa C. Southey,Gianluca Severi,Gianluca Severi,Jenny L Donovan,Freddie C. Hamdy,David P. Dearnaley,David P. Dearnaley,Kenneth Muir,Charmaine Smith,Melisa Bagnato,Audrey Ardern-Jones,Amanda L. Hall,Amanda L. Hall,Lynne T. O'Brien,Beatrice N. Gehr-Swain,Beatrice N. Gehr-Swain,Rosemary A. Wilkinson,Cox A,Sarah J Lewis,Paul M. Brown,Sameer Jhavar,Malgorzata Tymrakiewicz,Artitaya Lophatananon,Sarah L Bryant,Alan Horwich,Alan Horwich,Robert Huddart,Robert Huddart,Vincent Khoo,Vincent Khoo,Chris Parker,Chris Parker,C. R. J. Woodhouse,Alan Thompson,Tim Christmas,Chris Ogden,Cyril Fisher,Charles Jamieson,Colin Cooper,Dallas R. English,John L. Hopper,David E. Neal,Douglas F. Easton +55 more
TL;DR: A genome-wide association study using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at ≤60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml) identified seven loci associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19 and X.
Journal ArticleDOI
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot,Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert Huddart,Elizabeth A. Burgess,Mark D. Fleming,A. Rezazadeh,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Yousef Zakharia,B. Zhong,K. Stuyckens,A. Santiago-Walker,P. De Porre,A. O'Hagan,A. Avadhani,Arlene O. Siefker-Radtke +20 more
TL;DR: The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations.
Journal ArticleDOI
Radiotherapy with or without Chemotherapy in muscle-invasive bladder cancer
Nicholas D. James,Syed A. Hussain,Peter Jenkins,Jean Tremlett,Christine Rawlings,Malcolm Crundwell,Bruce Sizer,Thiagarajan Sreenivasan,Carey Hendron,Rebecca Lewis,Rachel Waters,Robert Huddart +11 more
TL;DR: Synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer, as compared with Radiotherapy alone, with no significant increase in adverse events.
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.